Therefore, in the present study, using a segmental osteoperiosteal bone defect (0.8 cm, in the middle of the left radius) that remained incompletely healed in all control rabbits for 6 weeks (assessed in 2-week intervals), pentadecapeptide BPC-157 was further studied (either percutaneously given locally [10 g/kg body weight] into the bone defect, or applied intramuscularly [intermittently, at postoperative days 7, 9, 14, and 16 at 10 g/kg body weight] or continuously [once per day, postoperative days 721 at 10 g or 10 ng/kg body weight])
These muscles can tolerate and will need a longer needle
Can Tiaminal B12 injection combinations be used for all patients
It matters more than the product rankings
Critics argue that the FDA's caution could restrict access to a potentially beneficial compound, advocating for a more balanced approach that considers BPC-157's therapeutic potential